Special Issue "Antibody Drug and Target Discovery for Cancer Therapies"
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (20 October 2022) | Viewed by 9592
Interests: single domain antibodies; antibody mimetics; intracellular antibodies; intracellular antibody-based degraders; protein-protein interaction inhibition; phage display; cell-based screening; cancer therapeutic targets; pancreatic cancer
Antibodies are a class of biological therapeutics that is quickly expanding with now more than 100 antibodies approved by the FDA. All of these drugs bind extracellular or transmembrane targets and most of them inhibit their target function by blocking receptor-ligand interactions. However, therapeutic antibodies are not limited to canonical antibodies and other avenues such as antibody-drug conjugate (ADC) or bispecific antibodies in oncoimmunology are exciting possibilities for cancer therapies. In the future, intracellular antibodies—i.e., expressed within the cells—may have a huge impact on cancer treatments once their delivery will be efficient for inhibiting intracellular targets in clinic.
This Special Issue of Antibodies aims to provide an up-to-date overview of therapeutic antibodies but also of the use of antibodies (or fragment antibodies) for discovering novel therapeutic targets of interest (either extra or intracellular ones) or novel inhibitory mechanisms and their validation. In this Special Issue, original research articles and reviews are welcome and should cover the aforementioned topics applied to cancer therapies.
Dr. Nicolas Bery
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- therapeutic targets
- intra or extracellular targets
- antibody drug conjugates
- cancer immunotherapy
- bispecific T-cell engager antibodies
- intracellular antibodies
- target validation
- novel inhibitory mechanisms